OSU-T315
| 中文名称 | OSU-T315 |
|---|---|
| 中文同义词 | ILK抑制剂(ILK-IN-2);ILK-IN-2游离态;N-甲基-3-(1-(4-(哌嗪-1-基)苯基)-3-(4'-(三氟甲基)-[1,1'-联苯基]-4-基)-1H-吡唑-5-基)丙胺;化合物ILK-IN-2;N-甲基-3-(1-(4-(哌嗪-1-基)苯基)-3-(4'-(三氟甲基)-[1,1'-联苯基]-4-基)-1H-吡唑-5-基)丙酰胺;化合物ILK-IN-2,10 MM DMSO 溶液;OSU-T315 ,S6840;OSU-T315试剂 |
| 英文名称 | ILK-IN-2 |
| 英文同义词 | ILK-IN-2;OSU-T315 (1,5-regioisomer);1H-Pyrazole-5-propanamide, N-methyl-1-[4-(1-piperazinyl)phenyl]-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-;OSU-T315 (ILK-IN-1);OSU-T315 (1,3-regioisomer);N-Methyl-3-(1-(4-(piperazin-1-yl)phenyl)-3-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)propanamide;Inhibitor,Integrin,OSU-T315,OSU-T-315,Apoptosis,inhibit,Autophagy,OSU T315,OSUT315;OSU-T315, 10 mM in DMSO |
| CAS号 | 2070015-22-2 |
| 分子式 | C30H30F3N5O |
| 分子量 | 533.59 |
| EINECS号 | |
| 相关类别 | 细胞生物学试剂;对照品 |
| Mol文件 | 2070015-22-2.mol |
| 结构式 |  |
OSU-T315 性质
| 沸点 | 739.234±60.00 °C(Press: 760.00 Torr)(predicted) |
|---|---|
| 密度 | 1.275±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| 储存条件 | 2-8°C(protect from light) |
| 溶解度 | DMSO：≥50mg/mL（93.70mM）；水：< 0.1 mg/mL（不溶） |
| 酸度系数(pKa) | 16.221±0.46(predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| Target | Value |
|
ILK
(Cell-free assay) | 0.6 μM |
OSU-T315 (Compound 22; 0-5 μM; 24 hours) exhibits high in vitro potency against a panel of prostate and breast cancer cell lines with a IC
50
range of 1-2.5 μM.
OSU-T315 (0-2.5 μM; 24 hours) can reduce YB-1, HER2, and EGFR expression; shows a modest suppressive effect on phosphorylated S6 levels, exhibits dose-dependent suppressive effects on the levels of phospho-ERK1/2 and phospho-p38, while that of phospho-JNK remains unaltered in PC-3 cell.
OSU-T315 (0-4 μM; 24 hours) causes autophagy through ILK inhibition.
Western Blot Analysis
| Cell Line: | PC-3 cells; MDA-MB-231 cells |
| Concentration: | 1 μM, 2 μM, 3 μM, 4 μM; 0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM |
| Incubation Time: | 24 hours |
| Result: | Exhibited a dose-dependent decreasing effect on the phosphorylation of pS6, ERKs, and p38 in PC-3 cells and MDA-MB-231 cells. |
Cell Viability Assay
| Cell Line: | Prostate cancer cells: LNCaP, PC-3; breast cancer cells: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7; PrEC and MEC cells |
| Concentration: | 0-5 μM |
| Incubation Time: | 24 hours |
| Result: | Suppressed cancer cells viability in breast and prostate cancer cells (IC (50), 1-2.5μM). |
Apoptosis Analysis
| Cell Line: | PC-3 cells |
| Concentration: | 1 μM, 2 μM, 3 μM, 4 μM |
| Incubation Time: | 24 hours |
| Result: | Induced accumulation of LC3-II and PARP cleavage. |
OSU-T315 (Oral gavage; 25 mg/kg, 50 mg/kg; single daily; 35 days) has a suppressive effect of on PC-3 xenograft tumor growth .
No other obvious toxicity is observed in mice.
| Animal Model: | Male NCr athymic nude mice with PC-3 tumor xenografts |
| Dosage: | 25 mg/kg; 50 mg/kg |
| Administration: | Oral gavage; single daily; 35 days |
| Result: | Resulted in suppression of tumor growth relative to the vehicle control after 35 days of treatment (48% and 62% suppression for 25 and 50 mg/kg, respectively). |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-18676 | OSU-T315 OSU-T315 | 2070015-22-2 | 1 mg | 1200元 |
| 2026/09/15 | HY-18676 | OSU-T315 OSU-T315 | 2070015-22-2 | 5 mg | 2900元 |